Navigation Links
Amarin Appoints Dr. William Mason as Lead Independent Director
Date:2/4/2008

LONDON, February 4 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRND) today announced that its Board of Directors has established the position of Lead Independent Director and has appointed current board member, Dr. William Mason, to that role. In his capacity as Lead Independent Director, Dr. Mason will have the authority to convene meetings of the independent directors, and will preside over those meetings, will coordinate the activities of the independent directors, and will act as a liaison between the independent directors, the Board and the Chairman.

The establishment of a Lead Independent Director and Dr. Mason's appointment to that position follows the recent announcement by Amarin that Thomas Lynch, Amarin's Chairman, has assumed the additional role of Chief Executive Officer of Amarin.

Mr. Lynch commented, "Dr. Mason's appointment as our Lead Independent Director reflects our ongoing commitment to maintaining high standards of corporate governance. Dr. Mason is a valued non-executive board member, and an experienced advisor to the pharmaceutical and biotechnology industry. We look forward to his continued contribution to our business."

Dr. Mason added, "I am pleased to accept the new role of Lead Independent Director and look forward to working with both Amarin's talented resource of independent directors, as well as with Thomas Lynch, our experienced Chairman and CEO, at what is a very exciting time for the Company. This is a valuable step in the evolution of our high standards of governance. Amarin's Board of Directors is committed to the highest level of corporate governance in our quest to achieve value for all of our shareholders."

Dr. Mason has served as a non-executive board member of Amarin since July 2002, is Chairman of the Company's Audit Committee and a member of Amarin's Nominations Committee. Dr. Mason received his B.Sc. from Case Western Reserve University in the United States and his doctorate in physiology from Trinity College, Cambridge, UK in 1977. For twenty years he led a program of neuroscience-focused medical research in Cambridge.

Dr. Mason also played an active role as a member of the Advisory Council on Science and Technology (ACOST) in the UK Cabinet Office of HM Government, developing government policy to create a highly qualified scientific and technical manpower base in the UK. He has founded successful high technology biomedical companies and has extensive commercial transactional experience in the healthcare and life sciences sector. He maintains strong links with the healthcare investment community. Currently, Dr. Mason is Chairman of OrthoMimetics Ltd., Camlab Ltd. and Team Consulting Ltd., and is a director of Sage Healthcare Ltd., Zygem Ltd. and Sphere Medical Ltd. He is also a member of the 3i Independent Director's Program.

About Amarin

Amarin is committed to improving the lives of patients suffering from central nervous system (CNS) and cardiovascular diseases. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs.

Amarin's CNS development pipeline includes the recently acquired myasthenia gravis clinical program and preclinical programs in neuromuscular, neuronal degenerative and inflammatory diseases; Miraxion for Huntington's disease; two programs in Parkinson's disease; one in epilepsy; and one in memory. Amarin is initiating a series of cardiovascular preclinical and clinical programs to capitalize on the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin also has two proprietary technology platforms, a lipid-based technology platform for the targeted transport of molecules through the liver and/or to the brain, and a unique mRNA technology based on cholinergic neuromodulation.

Amarin has its primary stock market listing in the U.S. on the NASDAQ Capital Market ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"), respectively. In accordance with customary Nasdaq practice, following Amarin's reverse stock split, which took effect from January 18, 2008, a "D" will be appended to Amarin's Nasdaq ticker symbol for a period of 20 trading days and during that period Amarin's Nasdaq ticker symbol will appear as "AMRND".


'/>"/>
SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
2. Amarin to Present at 4th Annual Bio Investor Forum
3. Amarin Announces Initiation of Cardiovascular Development Strategy
4. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
5. Amarin Signs Agreement to Acquire Ester Neurosciences
6. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
7. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
8. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
9. Codexis Appoints Singapore Laboratories Managing Director
10. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... NY (PRWEB) , ... February 24, 2017 , ... FireflySci, ... Founded in late 2014, FireflySci had the goal of bringing their powerful ... goal continues to shape the path that FireflySci is going on as they add ...
(Date:2/24/2017)... 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a ... Key Opinion Leader event to highlight new clinical data ... presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and ... be held in-person and via live webcast on Tuesday, ... PST at the Lotte New York Palace Hotel in ...
(Date:2/23/2017)... ... 2017 , ... BellBrook Labs is formalizing a significant expansion ... biochemical analyses critical for Lead Discovery. The company’s Lead Discovery Services will ... inhibitor potency and selectivity, mechanism of action, and inhibitor residence times on drug ...
(Date:2/23/2017)... -- In Atlanta, it seems everyone has a chance to express ... an expressive and dynamic community unlike any other. The businesses ... it. With their newest salon in ... carry on that tradition with a unique, fresh approach to ... is the newest of 13 nationwide locations, each of them ...
Breaking Biology Technology:
(Date:2/3/2017)... , Feb. 3, 2017 A new ... Identity Strategy Partners, LLP (IdSP) . Designed to fill ... the complex identity market, founding partners Mark Crego ... 35 combined years just in identity expertise that span ... and non-profit leadership. The Crego-Kephart combined expertise has a ...
(Date:2/1/2017)... 2017 IDTechEx Research, a leading provider of ... the availability of a new report, Sensors for Robotics: Technologies, ... Reading ... ... Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: ...
(Date:1/26/2017)... -- Acuity Market Intelligence today released the 2017 "Ten ... characterizes 2017 as a "breakout" year for biometrics ... new understanding of the potential benefits these technologies ... are often perceived as threats to privacy and ... Acuity Market intelligence. "However, taken together these technologies ...
Breaking Biology News(10 mins):